A Phase 3 interventional study of Ranibizumab and Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) in Macular Degeneration, sponsored by Bayer. Completed at 189 sites in 26 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2014-12-12.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing aflibercept in Macular Degeneration — 3 open to participants now, 6 under way, 2 of them phase 3. aflibercept · Macular Degeneration.
Among the 67 studies testing aflibercept in Macular Degeneration, this one has the largest enrollment, is the only one that started in 2008, is one of 18 in phase 3, and was the 5th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.
Browse Macular Degeneration studies →3 of the 67 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:
Amgen · Sites in United States, Czechia, Hungary and 6 more countries
Ages 50+
Honghua Yu,MD
Ages 50+
Tianjin Medical University Eye Hospital
Ages 50–85
By country, each count listing its studies:
aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 19 · Phase 4 28
First in 2005; this study’s year is marked. 1 started in 2008.
This study's enrollment of 1,240 is above the median of 56 across 986 interventional studies indexed under Macular Degeneration.
Median enrollment 54 across the 67 interventional studies. Of the 48 that completed or were terminated, 28 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
31 of 67 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
30 studies in Macular Degeneration by Bayer: none open now, 1 under way, none of them phase 3. Of 29 finished, 10 (34%) have results posted.
Among the 30 studies in Macular Degeneration by Bayer, this one has the largest enrollment of the 10 interventional ones that give a count, is the only one that started in 2008, is one of 4 in phase 3, and was the 1st registered.
Bayer’s Macular Degeneration studies by the year they started, since 2008.
2 of the studies testing aflibercept in Macular Degeneration that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07614776Phase 3AmgenA Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration | 2027-07-31 |
| NCT04932980Berner AugenklinikComparison of Rapid Aflibercept and Brolucizumab T&E in wAMD | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 67 studies testing aflibercept in Macular Degeneration, from their registry updates:
Among Bayer’s 30 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.
Data of this trial ("VIEW 2") was pooled with data of a sister trial ("VIEW 1", NCT00509795), and an integrated analyses of the combined data was performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Drug: Ranibizumab
Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)
Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)
Maintenance of vision was defined as a loss of \< 15 letters in the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score (defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: At week 52
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Time frame: Baseline and at week 52
Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
Time frame: At week 52
Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF
The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).
Time frame: Baseline and at week 52
Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF
CNV area values measured in square millimeters; lower values represent better outcomes.
Time frame: Baseline and at week 52
The study was conducted at 186 study centers in 26 countries. Recruitment period: 21 Apr 2008 - 4 Sep 2009.
| Milestone | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 |
|---|---|---|---|---|
| Started | 303 | 313 | 311 | 313 |
| Participants received treatment | 291 | 309 | 297 | 307 |
| Participants treated (fas) | 291 | 309 | 296 | 306 |
| Completed | 276 | 281 | 274 | 284 |
| Not completed | 27 | 32 | 37 | 29 |
| Withdrew: Adverse event | 2 | 6 | 8 | 9 |
| Withdrew: Death | 1 | 3 | 2 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 4 | 1 | 2 | 2 |
| Withdrew: Protocol violation | 2 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 11 | 15 | 13 | 11 |
| Withdrew: Other (no further information available) | 7 | 6 | 10 | 5 |
Maintenance of vision was defined as a loss of \< 15 letters in the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score (defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 |
|---|---|---|---|---|
| Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF) | 94.42 | 95.62 | 96.27 | 95.56 |
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
| Letters correctly read | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 |
|---|---|---|---|---|
| Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF | 9.4 ± 13.5 | 7.6 ± 12.6 | 9.7 ± 14.1 | 8.9 ± 14.4 |
Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.
| Percentage of participants | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 |
|---|---|---|---|---|
| Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF | 34.02 | 29.45 | 34.80 | 31.37 |
The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).
| Scores on a scale | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 |
|---|---|---|---|---|
| Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF | 6.3 ± 14.8 | 4.5 ± 15.0 | 5.1 ± 13.7 | 4.9 ± 14.7 |
CNV area values measured in square millimeters; lower values represent better outcomes.
| mm^2 | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 |
|---|---|---|---|---|
| Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF | -4.16 ± 5.90 | -5.95 ± 6.12 | -4.24 ± 6.13 | -5.16 ± 5.87 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5mg Q4 | — | 65/291 (22.3%) | 254/291 (87.3%) |
| Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | — | 81/309 (26.2%) | 259/309 (83.8%) |
| Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | — | 72/297 (24.2%) | 251/297 (84.5%) |
| Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 | — | 81/307 (26.4%) | 260/307 (84.7%) |
| Event | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 |
|---|---|---|---|---|
| Visual acuity reducedEye disorders | 3/291 | 5/309 | 1/297 | 7/307 |
| PneumoniaInfections and infestations | 1/291 | 4/309 | 2/297 | 6/307 |
| CataractEye disorders | 5/291 | 4/309 | 4/297 | 4/307 |
| Myocardial infarctionCardiac disorders | 4/291 | 3/309 | 3/297 | 4/307 |
| Retinal haemorrhageEye disorders | 4/291 | 3/309 | 4/297 | 2/307 |
| Retinal detachmentEye disorders | 3/291 | 0/309 | 1/297 | 0/307 |
| Chest painGeneral disorders | 3/291 | 1/309 | 1/297 | 1/307 |
| Upper limb fractureInjury, poisoning and procedural complications | 2/291 | 1/309 | 3/297 | 0/307 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/291 | 0/309 | 3/297 | 1/307 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/291 | 0/309 | 3/297 | 1/307 |
| Event | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 |
|---|---|---|---|---|
| Retinal haemorrhageEye disorders | 82/291 | 84/309 | 70/297 | 82/307 |
| Visual acuity reducedEye disorders | 46/291 | 44/309 | 55/297 | 60/307 |
| Macular degenerationEye disorders | 37/291 | 35/309 | 42/297 | 51/307 |
| Conjunctival haemorrhageEye disorders | 34/291 | 33/309 | 46/297 | 35/307 |
| HypertensionVascular disorders | 42/291 | 41/309 | 33/297 | 34/307 |
| NasopharyngitisInfections and infestations | 39/291 | 25/309 | 32/297 | 26/307 |
| Detachment of retinal pigment epitheliumEye disorders | 38/291 | 37/309 | 33/297 | 31/307 |
| Retinal oedemaEye disorders | 34/291 | 32/309 | 31/297 | 40/307 |
| Intraocular pressure increasedInvestigations | 37/291 | 38/309 | 24/297 | 29/307 |
| Age-related macular degenerationEye disorders | 26/291 | 28/309 | 26/297 | 38/307 |
| Age, Continuous(years) | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 | Total |
|---|---|---|---|---|---|
| Mean | 73.0 ± 9.0 | 74.1 ± 8.5 | 74.7 ± 8.6 | 73.8 ± 8.6 | 73.9 ± 8.7 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 | Total |
|---|---|---|---|---|---|
| Female | 169 | 176 | 147 | 175 | 667 |
| Male | 122 | 133 | 149 | 131 | 535 |
| Ethnicity(participants) | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 | Total |
|---|---|---|---|---|---|
| Not Hispanic or Latino | 239 | 259 | 241 | 251 | 990 |
| Hispanic or Latino | 52 | 50 | 55 | 55 | 212 |
| Race(participants) | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 | Total |
|---|---|---|---|---|---|
| White | 213 | 226 | 219 | 217 | 875 |
| Black or African American | 1 | 0 | 1 | 2 | 4 |
| Asian | 60 | 67 | 61 | 69 | 257 |
| Missing | 17 | 16 | 15 | 18 | 66 |
| National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total score(scores on a scale) | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 | Total |
|---|---|---|---|---|---|
| Mean | 72.90 ± 19.09 | 70.27 ± 19.41 | 74.04 ± 18.22 | 71.30 ± 19.06 | 72.10 ± 18.99 |
| Area of Choroidal Neovascularization (CNV)(mm^2) | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 | Total |
|---|---|---|---|---|---|
| Mean | 7.59 ± 5.34 | 8.25 ± 5.77 | 7.70 ± 5.26 | 7.75 ± 5.52 | 7.83 ± 5.48 |
| Baseline lesion type(participants) | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 | Total |
|---|---|---|---|---|---|
| Predominantly classic | 70 | 72 | 80 | 88 | 310 |
| Minimally classic | 104 | 112 | 103 | 106 | 425 |
| Occult | 116 | 123 | 113 | 110 | 462 |
| Missing | 1 | 2 | 0 | 2 | 5 |
| Baseline total lesion size(mm^2) | Ranibizumab 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4 | Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8 | Total |
|---|---|---|---|---|---|
| Mean | 8.01 ± 5.74 | 8.72 ± 6.14 | 8.17 ± 5.51 | 8.22 ± 5.87 | 8.28 ± 5.82 |
1 further baseline measures are reported on the registry.
Showing the first 100 of 189 sites across 26 countries. Choose a country and city above to see the rest.
The record gives a start of Apr 2008, a primary completion of Sep 2010 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept